U.S., Nov. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07223125) titled 'A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors' on Oct. 30.
Brief Summary: The purpose of this study is to determine safe and effective dose (recommended phase 2 doses [RP2Ds]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.
Study Start Date: Oct. 10
Study Type: INTERVENTIONAL
Condition:
Advanced-stage Solid Tumors
Intervention:
DRUG: JNJ-89862175
JNJ-89862175 will be administered.
Recruitment Status: RECRUITING
Sponsor: Janssen Research & Development, LLC
Published by HT Di...